Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Qurish Mohemmad"'
Autor:
Victor M. Rivera, William C. Shakespeare, David Dalgarno, Tim Clackson, Xiaotian Zhu, Juan Miret, Frank Wang, Narayana Narasimhan, Emily Ye, Hyun Gyung Jang, Qurish Mohemmad, Yihan Wang, Dong Zou, Shuangying Liu, Wei-Sheng Huang, Lauren Moran, Lindsey Eichinger, Youngchul Song, David Miller, Scott D. Wardwell, Yaoyu Ning, Jeff Keats, Tianjun Zhou, Sara Nadworny, Rachel Squillace, Rana Anjum, Sen Zhang
Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5126f7a2057f9c47635f6496d280ebf0
https://doi.org/10.1158/1078-0432.c.6525524.v1
https://doi.org/10.1158/1078-0432.c.6525524.v1
Autor:
Victor M. Rivera, William C. Shakespeare, David Dalgarno, Tim Clackson, Xiaotian Zhu, Juan Miret, Frank Wang, Narayana Narasimhan, Emily Ye, Hyun Gyung Jang, Qurish Mohemmad, Yihan Wang, Dong Zou, Shuangying Liu, Wei-Sheng Huang, Lauren Moran, Lindsey Eichinger, Youngchul Song, David Miller, Scott D. Wardwell, Yaoyu Ning, Jeff Keats, Tianjun Zhou, Sara Nadworny, Rachel Squillace, Rana Anjum, Sen Zhang
Supplementary Table 1. Brigatinib in vitro activity (IC50s) in a kinase panel (N=289); Supplementary Figure 1. Chemical structures of brigatinib, crizotinib, ceritinib, and alectinib; Supplementary Figure 2. Brigatinib-mediated inhibition of native o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c6bdb6961073a5b3e650ddfb94203a6
https://doi.org/10.1158/1078-0432.22463789.v1
https://doi.org/10.1158/1078-0432.22463789.v1